Verily Life Sciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

verily.com

Stage

Acquired

Total Raised

$2.5B

Investors Count

5

Portfolio Exits

6

Investments

17

Verily Life Sciences Funding, Verily Life Sciences Valuation & Verily Life Sciences Revenue

4 Fundings

Verily Life Sciences's latest funding round was a Private Equity - II for $700M on December 17, 2020.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/17/2020

Private Equity - II

$700M

Alphabet, Silver Lake, Temasek, and Undisclosed Investors

0

FY undefined

7

1/3/2019

Private Equity

$99M

0

FY undefined

10

1/26/2017

Corporate Minority

$99M

0

FY undefined

10

1/1/2015

Spinoff / Spinout

0

FY undefined

10

Date

12/17/2020

1/3/2019

1/26/2017

1/1/2015

Round

Private Equity - II

Private Equity

Corporate Minority

Spinoff / Spinout

Amount

$700M

$99M

$99M

Investors

Alphabet, Silver Lake, Temasek, and Undisclosed Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

7

10

10

10

Verily Life Sciences Investors

5 Investors

Verily Life Sciences has 5 investors. Temasek invested in Verily Life Sciences's Private Equity - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/26/2017

12/17/2020

2
Corporate Minority, Private Equity - II (2020)

Public-Private Partnership

Singapore

00/00/0000

00/00/0000

Silver Lake

Subscribe to see more

Private Equity

California

00/00/0000

00/00/0000

Alphabet

Subscribe to see more

Holding Company

California

00/00/0000

00/00/0000

Ontario Teachers' Pension Plan

Subscribe to see more

Pension Fund

Canada

00/00/0000

00/00/0000

X - The Moonshot Factory

Subscribe to see more

Corporation

California

First funding

1/26/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

12/17/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Silver Lake

Alphabet

Ontario Teachers' Pension Plan

X - The Moonshot Factory

Rounds

2
Corporate Minority, Private Equity - II (2020)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Public-Private Partnership

Private Equity

Holding Company

Pension Fund

Corporation

Location

Singapore

California

California

Canada

California

Verily Life Sciences Acquisitions

2 Acquisitions

Verily Life Sciences acquired 2 companies. Their latest acquisition was SignalPath on August 17, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/17/2021

Debt

$99M

$35.46M

Acquired

2

9/10/2014

Seed / Angel

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/17/2021

9/10/2014

Investment Stage

Debt

Seed / Angel

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$35.46M

$99M

Note

Acquired

Subscribe to see more

Sources

2

10

Verily Life Sciences Investments

17 Investments

Verily Life Sciences has made 17 investments. Their latest investment was in Syllable as part of their Series C on April 4, 2022.

CBI Logo

Verily Life Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/25/2022

Series C

Syllable

$40M

Yes

2

3/30/2022

Seed VC

Zephyr AI

$18.5M

Yes

9

10/14/2021

Series B

Culture Biosciences

$80M

No

14

4/29/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

1/11/2021

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/25/2022

3/30/2022

10/14/2021

4/29/2021

1/11/2021

Round

Series C

Seed VC

Series B

Seed VC

Series E

Company

Syllable

Zephyr AI

Culture Biosciences

Subscribe to see more

Subscribe to see more

Amount

$40M

$18.5M

$80M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

9

14

10

10

Verily Life Sciences Portfolio Exits

6 Portfolio Exits

Verily Life Sciences has 6 portfolio exits. Their latest portfolio exit was Ciitizen on September 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/7/2021

Acquired

$99M

5

3/3/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/20/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/9/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/1/2016

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/7/2021

3/3/2021

12/20/2019

5/9/2019

8/1/2016

Exit

Acquired

IPO

Acquired

IPO

Corporate Majority

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

You May Also Like

Cardionomic Logo
Cardionomic

Cardionomic addresses Acute Decompensated Heart Failure's root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality.

N
Neuspera Medical

Neuspera Medical is a medical device startup that leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies, sometimes referred to as electroceuticals. Neuspera's implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication, and post-surgical pain. Neuspera Medical is committed to bringing forward implantable medical device technology that will improve lives of patients battling with chronic illness.

S
ShiraTronics

ShiraTronics develops an approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical is developing a bioelectronic medicine platform using a small implanted device that activates the body's natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.

L
LivaNova

LivaNova is a medical device company in the treatment of cardiovascular diseases. The company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

B
Brainsgate

BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.